Progression of renal amyloidosis is associated with severe proteinuria or nephrotic syndrome, and various mechanisms have been postulated to explain these complications. We studied the acceleration of proteinuria and reduced renal function by cluster analysis using clinical parameters, renal histological findings, type of renal amyloidosis and follow-up data. We divided 97 cases into three groups of renal amyloidosis. Accelerated progression correlated with serum creatinine (s-Cr) levels at renal biopsy and histological grade of renal damage by amyloid deposition (p < 0.0001). The most influential prognostic factors (s-Cr level ≧2.0 mg/dl) were tubulointerstitial and vascular damage induced by amyloid deposition at biopsy (odds ratio 96.9 and 69.2, respectively). In addition, we found amyloidosis type amyloid associated (AA) correlated with more amyloid-mediated vascular and tubulointerstitial damage than amyloidosis type amyloid light chain (AL) (p < 0.001, p < 0.01, respectively). Proteinuria and nephrotic syndrome were more severe in cases of amyloidosis AL than in amyloidosis AA (p = 0.076). In conclusion, less tubulointerstitial and vascular damage was caused by amyloid deposition; this was slowly progressive. Amyloid AA was detected in tubulointerstitial tissue and vessels more frequently than amyloid AL. Heavy proteinuria and/or nephrosis were not indicators of rapid progression.

Keywords:
Renal amyloidosis, Amyloid AA and AL, Cluster analysis, Progression style, Grade of histological damage
1.
Dikman SH, Churgh J, Kahn T: Morphologic and clinical correlates in renal amyloidosis. Hum Pathol 1981;12:160.
2.
Tornroth T, Falck HM, Wafin F, Wegelius O: Renal amyloidosis in rheumatic disease: A clinicopathological relative study; in Glenner GG, de Costa PP, de Freitas (eds): Amyloid and Amyloidosis. Amsterdam, Excerpta Medica, 1980, pp 191–199.
3.
Bohle A, Wehrmann M, Eissele R, von Gise H, Mackensen Haen S, Muller C: The long-term prognosis of AA and AL renal amyloidosis and the pathogenesis of chronic renal failure in renal amyloidosis. Pathol Res Pract 1993;189:316–331.
4.
Makino H, Nagake Y, Murakami K, Hirakawa S, Ota Z: Remission of nephrotic syndrome in a patient with renal amyloidosis associated with Takayasu’s arteritis after treatment with dimethylsulphoxide. Ann Rheum Dis 1994;53:842–843.
5.
Maezawa A, Hiromura K, Mitsuhashi H, Tsukada Y, Kanai H, Yano S, Naruse T: Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 1994;42:30–32.
6.
Lowenstein J, Gallo G: Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med 1970;282:128–132.
7.
Eiji M: Cluster analysis; Haruo Y, Hirofumi T (eds): Multiple Analysis Handbook. Kyoto, Gendaisuugakusya, 1995, pp 224–242.
8.
Gay FW, Drye TJ, Dick GWA, Esiri MM: The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997;120:1461–1483.
9.
Rumpelt HJ, Steinke A, Thoenes W: Alport-type glomerulopathy: Evidence for diminished capillary loop size. Clin Nephrol 1992;37:57–64.
10.
Ishitobi F, Sagiya A, Ueda Y, Oka K, Kanaya H, Iidaka K: Morphometric analysis of the glomerular capillary area – A comparison of minimal-change nephrotic syndrome, focal glomerular sclerosis, and preeclampsia. J Pathol 1991;165:329–336.
11.
Toth T, Takebayashi S: Glomerular hypertrophy as a prognostic marker in childhood IgA nephropathy. Nephron 1998;80:285–291.
12.
Ward JH: Hierarchical grouping to optimize an objective function. J Am Stat Assoc 1963;58:236–244.
13.
Shiiki H, Shimokama T, Yoshikawa Y, Toyoshima H, Kitamoto T, Watanabe T: Renal amyloidosis. Correlations between morphology, chemical types of amyloid protein and clinical features. Virchows Arch [A] 1988;412:197–204.
14.
Bosch X, Campistol JM, Almirall J, Torras A, Pedrol E, Botey A, Revert L: Subacute kidney insufficiency in exclusively vascular kidney amyloidosis (in Spanish). Med Clin (Barc) 1990;94:140–142.
15.
Goldsmith DJ, Sandooran D, Short CD, Mallick NP, Johnson RW: Twenty-one year survival with systemic AL amyloidosis. Am J Kidney Dis 1996;28:278–282.
16.
Jones BA, Shapiro HS, Rosenberg BF, Bernstein J: Minimal renal amyloidosis with nephrotic syndrome. Arch Pathol Lab Med 1986;110:889–892.
17.
Von Gise H, Helmchen U, Mikeler E, Bruning L, Walther C, Christ H, Mackenson S, Bohle A: Correlations between the morphological and clinical findings in a patient recovering from secondary generalised amyloidosis with renal involvement. Virchows Arch [A] 1978;379:119–129.
18.
Von Gise H, Mikeler E, Gruber M, Christ H, Bohle A: Investigations of the cause of the nephrotic syndrome in renal amyloidosis. Virchows Arch [A] 1978;379:131–141.
19.
Katafuchi R, Taguchi T, Takebayashi S, Harada T: Proteinuria in amyloidosis correlates with epithelial detachment and distortion of amyloid fibrils. Clin Nephrol 1984;22:1–8.
20.
Shiiki H, Shimokama T, Yoshikawa Y, Onoyama K, Morimatsu M, Watanabe T: Perimembranous-type renal amyloidosis: A peculiar form of AL amyloidosis. Nephron 1989;53:27–32.
21.
Hershkoviz R, Preciado-Patt L, Lider O, Fridkin M, Dastych J, Metcalfe DD, Medori YA: Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Am J Physiol 1997;273:C179–C187.
22.
Moroni G, Banfi G, Maccario M, Mereghetti M, Ponticelli C: Extracapillary glomerulonephritis and renal amyloidosis. Am J Kidney Dis 1996;28:695–699.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.